Conventional therapies fail to target inflammation and immune imbalance in subjects with stable coronary artery disease: A system-based approach

Atherosclerosis

Volumn 237, Issue 2, 2014, Pages 623-631

  Kapoor, Divya ^a   Trikha, Dimple ^a   Vijayvergiya, Rajesh ^a   Kaul, Deepak ^a   Dhawan, Veena ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Coronary artery disease (CAD); Gene expression; Immune imbalance; Inflammation; Micro array

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATING TRANSCRIPTION FACTOR 3; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CXCR4; CHOLESTEROL; CXCL2 CHEMOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; ONCOSTATIN M; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATASE; PROSTAGLANDIN SYNTHASE; PROTEIN DUSP 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BIOINFORMATICS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG POTENCY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNE IMBALANCE; IMMUNE SYSTEM; INFLAMMATION; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84910630476     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.10.009     Document Type: Article

References (47)

1. Hansson M.A., Fareed M.T., Argenio S.L., Agunwamba A.O., Hanson T.R. Coronary artery disease. Prim. Care 2013, 40:1-16.
2. Libby P., Theroux P. Pathophysiology of coronary artery disease. Circulation 2005, 111:3481-3488.
3. El-Menyar A.A. Cytokines and coronary artery disease: the state of the art. Crit. Pathw. Cardiol. 2008, 7:139-151.
4. Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335-2362.
5. Mihos C.G., Pineda A.M., Santana O. Cardiovascular effects of statins, beyond lipid-lowering properties. Pharmacol. Res. 2014, 10.1016/j.phrs.2014.02.009.
6. Krum H., Driscoll A. Management of heart failure. Med. J. Aust. 2013, 2(199):334-339.
7. Daviglus M.L., Lloyd-Jones D.M., Pirzada A. Preventing cardiovascular disease in the 21st century: therapeutic and preventive implications of current evidence. Am. J. Cardiovasc Drugs 2006, 6:87-101.
8. Aziz H., Zaas A., Ginsburg G.S. Peripheral blood gene expression profiling for cardiovascular disease assessment. Genomics Med. 2007, 1:105-112.
9. Wingrove J.A., Daniels S.E., Sehnert A.J., et al. Correlation of peripheral blood gene expression with the extent of coronary artery stenosis. Circ. Cardiovasc Genet. 2008, 1:31-38.
10. Timofeeva A.V., Goryunova L.E., Khaspekov G.L., et al. Altered gene expression pattern in peripheral blood leukocytes from patients with arterial hypertension. Ann. N. Y. Acad. Sci. 2006, 1091:319-335.
11. Stamova B., Xu H., Jickling G., Bushnell C., et al. Gene expression profiling of blood for the prediction of ischemic stroke. Stroke 2010, 41:2171-2177.
12. Sinnaeve P.R., Donahue M.P., Grass P., et al. Gene expression patterns in peripheral blood correlate with the extent of coronary artery disease. PLoS One 2009, 4:e7037.
13. Szauter M.K., Jansen K.M., Okimoto G., et al. Persistent inflammatory pathways associated with Early Onset myocardial infarction in a medicated Multiethnic Hawaiian cohort. Biochem. Insights 2011, 4:13-27.
14. World medical association declaration of Helsinki Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc Res. 1997, 35:2-3.
15. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
16. Irizarry R.A., Hobbs B., Collin F., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
17. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 2008, 3:1101-1108.
18. Kaul U., Varma J., Kahali D., et al. Post-marketing study of clinical experience of atorvastatin 80 mg vs 40 mg in Indian patients with acute coronary syndrome- a randomized, multi-center study (CURE-ACS). J.Assoc. Phys. India 2013, 61:97-101.
19. Bozbaş H., Mermer S., Yildirir A., et al. Pravastatin therapy fails to suppress post-PCI inflammatory response measured by serum neopterin and CRP levels. Anadolu Kardiyol. Derg. 2011, 11:207-212.
20. Fichtenbaum C.J., Yeh T.M., Evans S.R., Aberg J.A. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles, but not inflammatory markers in ACTG 5087. J.Clin. Lipidol. 2010, 4:279-287.
21. Nilsson L., Eriksson P., Cherfan P., Jonasson L. Effects of simvastatin on proinflammatory cytokines and matrix metalloproteinases in hypercholesterolemic individuals. Inflammation 2011, 34:225-230.
22. Balk E.M., Lau J., Goudas L.C., et al. Effects of statins on non-lipid serum markers associated with cardiovascular disease a systematic review. Ann. Intern Med. 2003, 139:670-682.
23. Ridker P.M. C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. Clin. Chem. 2009, 55:209-215.
24. Mahajan N., Malik N., Bahl A., Dhawan V. Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis 2009, 207:597-602.
25. Tiret L., Godefroy T., Lubos E., et al. Athero gene Investigators. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 2005, 112:643-650.
26. Khan D.A., Ansari W.M., Khan F.A. Pro/anti-inflammatory cytokines in the pathogenesis of premature coronary artery disease. J.Interferon Cytokine Res. 2011, 31:561-567.
27. Liang X., He M., Chen T., et al. Multiple roles of SOCS proteins: differential expression of SOCS1 and SOCS3 in atherosclerosis. Int. J. Mol. Med. 2013, 31:1066-1074.
28. Azijli K., Yuvaraj S., van Roosmalen I., et al. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1. Apoptosis 2013, 18:851-860.
29. Liu Z.J., Tan Y., Beecham G.W., et al. Notch activation induces endothelial cell senescence and pro-inflammatory response: implication of Notch signaling in atherosclerosis. Atherosclerosis 2012, 225:296-303.
30. Schauer I.E., Knaub L.A., Lloyd M., et al. CREB Downregulation in vascular disease: a common response to cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 2010, 30:733-741.
31. Abraham S.M., Clark A.R. Dual-specificity phosphatase 1: a critical regulator of innate immune responses. Biochem. Soc. Trans. 2006, 34:1018-1023.
32. Khan T.A., Bianchi C., Araujo E.G., et al. Cardiopulmonary bypass reduces peripheral microvascular contractile function by inhibition of mitogen-activated protein kinase activity. Surgery 2003, 134:247-254.
33. Tsujita E., Taketomi A., Gion T., et al. Suppressed MKP-1 is an independent predictor of outcome in patients with hepatocellular carcinoma. Oncology 2005, 69:342-347.
34. Hägg S., Skogsberg J., Lundström J., et al. Multi-organ expression profiling uncovers a gene module in coronary artery disease involving trans endothelial migration of leukocytes and LIM domain binding 2: the Stockholm Atherosclerosis Gene Expression (STAGE) study. PLoS Genet. 2009, 5:e1000754.
35. Hägg S., Alserius T., Noori P., et al. Blood levels of dual-specificity phosphatase-1 independently predict risk for post-operative morbidities causing prolonged hospitalization after coronary artery bypass grafting. Int. J. Mol. Med. 2011, 27:851-857.
36. Zhang L., Li J., Liang A., Liu Y., Deng B., Wang H. Immune-related chemotactic factors were found in acute coronary syndromes by Bioinformatics. Mol. Biol. Rep. 2014, 10.1007/s11033-014-3310-7.
37. Gargalovic P.S., Gharavi N.M., Clark M.J., et al. The unfolded protein response is an important regulator of inflammatory genes in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2490-2496.
38. Tabas I. The role of endoplasmic reticulum stress in the progression of atherosclerosis. Circ. Res. 2010, 107:839-850.
39. Richards C.D. The enigmatic cytokine oncostatin M and roles in disease. SRN Inflamm. 2013, 512103.
40. Modur V., Feldhaus M.J., Weyrich A.S., et al. Oncostatin M is a proinflammatory mediator: invivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J.Clin. Invest 1997, 100:158-168.
41. Li X., Zhang X., Wei L., Xia Y., Guo X. Relationship between serum oncostatin M levels and degree of coronary stenosis in patients with coronary artery disease. Clin. Lab. 2014, 60:113-118.
42. Marin V., Montero-Julian F.A., Grès S., et al. The IL-6-soluble IL-6Rα autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin. J.Immunol. 2001, 167:3435-3442.
43. Boisvert W.A. Modulation of atherogenesis by chemokines. Trends Cardiovasc Med. 2004, 14:161-165.
44. Romuk E., Skrzep-Poloczek B., Wojciechowska C., et al. Selectin-P and interleukin-8 plasma levels in coronary heart disease patients. Eur. J. Clin. Invest 2002, 32:657-661.
45. Zhou R.H., Shi Q., Gao H.Q., Shen B.J. Changes in serum interleukin-8 and interleukin-12 levels in patients with ischemic heart disease in a Chinese population. J.Atheroscler. Thromb. 2001, 8:30-32.
46. Inoue T., Komoda H., Nonaka M., Kameda M., Uchida T., Node K. Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int. J. Cardiol. 2008, 124:319-325.
47. Ma J., Dempsey A.A., Stamatiou D., Marshall K.W., Liew C.C. Identifying leukocyte gene expression patterns associated with plasma lipid levels in human subjects. Atherosclerosis 2007, 191:63-72.